Dengue Literature Review

DENV-3

5 min read

DENV-3

Overview

DENV-3 is one of the four dengue virus serotypes. In Cuba, DENV-3 caused the 2001 epidemic — the third serotype introduction to Cuba after DENV-1 (1977) and DENV-2 (1981), meaning Cuban adults infected in 2006 (Garcia2009/2010 cohort) typically had DENV-1/2/3 prior infection history and DENV-4 was their fourth serotype encounter. Globally, DENV-3 shows notable within-serotype strain displacement dynamics and genotype changes associated with shifts in epidemic potential.

Key Points from Literature

  • Some DENV-3 strains replicate at higher rates in mosquitoes than other strains, conferring the capacity to displace established DENV-3 strains in a population. Similar displacement dynamics have been observed with DENV-2 in the South Pacific and DENV-4 in Puerto Rico — suggesting within-serotype competitive dynamics are epidemiologically significant (see Guzman2016 - Dengue Infection).
  • In Sri Lanka, DENV-3 genotype changes were associated with shifts in endemic and epidemic transmission intensity, further linking molecular evolution to outbreak dynamics (see Guzman2016 - Dengue Infection).
  • The Cuban serial serotype introduction sequence (DENV-1 → DENV-2 → DENV-3 → DENV-4) provided a unique natural experiment: 12/26 (46%) of the autoimmune marker subset in Garcia2009 had tetravalent infection history, making DENV-3 a likely contributor to the complex secondary/tertiary immune backgrounds underlying post-dengue syndrome in that cohort (see Garcia2009 - Long-term Clinical Symptoms Post-Dengue).
  • Most genetic changes associated with increased epidemic potential in DENV-3 (and other serotypes) result in amino acid changes in NS proteins — underscoring the role of NS proteins in determining host-pathogen interactions beyond immune evasion (see Guzman2016 - Dengue Infection).

CNS Tropism and Neuropathogenesis

Like DENV-2, DENV-3 is specifically implicated in direct CNS invasion causing encephalitis. This serotype-specific neurotropism is one of the three recognised pathways to dengue neurological disease, alongside metabolic encephalopathy and autoimmunity-mediated complications such as ADEM (see Dengue Neurological Complications, Shih2023 - Autoimmune Disease Risk After Dengue).

Singapore 2005 Outbreak

  • DEN-3 was a minor co-circulating serotype in Singapore during the October–November 2005 outbreak: 6 of 27 virologically typed patients (22%) had DEN-3, alongside the dominant DEN-1 (74%) and a single DEN-4 case (see Seet2007 - Post-Infectious Fatigue Syndrome in Dengue).
  • This co-circulation of DEN-1 and DEN-3 in Singapore in 2005 is consistent with the multi-serotype endemic pattern typical of Southeast Asian dengue settings, distinct from the serial introduction pattern seen in Cuba (where DENV-3 was introduced as the third serotype in 2001 after DENV-1 [1977] and DENV-2 [1981]).

Brazil 2007 — São Paulo State Outbreak

Jardim2012 - Autoimmune Features DHF Case Report documents a DENV-3 outbreak in São Paulo state (Brazil), confirmed by the São Paulo State Department of Health, active in May 2007. A 25-year-old woman with secondary dengue (IgM+/IgG+ serology) developed DHF with triple serositis, DIC, ANA 1/320 (mitotic spindle pattern), cryoglobulinemia, and selective C3 depression — all resolving at follow-up. This is the first Brazilian DENV-3 case in this wiki and confirms DENV-3 community transmission in Brazil at that time (n=1 case report — not generalizable as an epidemiological source).

Taiwan 1998–1999 Outbreak — Anti-Platelet IgM Data

Lin2001 - IgM Anti-Platelet Autoantibody in Dengue Patients studied a DENV-3 outbreak in southern Taiwan (November 1998–January 1999) confirmed and reported by the Taiwan CDC. Nine patients (5 DF, 4 DHF/DSS) provided serum at three timepoints (acute, convalescent, 8–9 months). Key finding: anti-platelet IgM was present in both DF and DHF/DSS patients and persisted for 8–9 months; DHF/DSS patients had higher anti-platelet IgM levels than DF in the acute phase. Crucially, most patients in this outbreak had primary DENV-3 infection (confirmed by haemagglutination inhibition assay), establishing that anti-platelet IgM generation does not require prior dengue exposure (see NS1 Molecular Mimicry in Dengue).

Contradictions & Debates

None yet recorded.

Sources

Graph View

Backlinks